1.
Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral Therapy
by Tovar Salazar, Adriana
AIDS research and human retroviruses, 2019, Vol.35 (10), p.89-895
2.
Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety
AIDS research and human retroviruses, 2020, Vol.36 (9), p.697-702
3.
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
by Thorpe, Kevin E
Journal of clinical epidemiology, 2009, Vol.62 (5), p.464-475
4.
Effectiveness of an 8-Week Aerobic Exercise Program on Autonomic Function in People Living with HIV Taking Anti-Retroviral Therapy: A Pilot Randomized Controlled Trial
AIDS research and human retroviruses, 2020, Vol.36 (4), p.283-290
5.
Use of altered informed consent in pragmatic clinical research
by McKinney, Ross E
Clinical trials (London, England), 2015, Vol.12 (5), p.494-502
6.
A Heavy Burden: Preexisting Physical and Psychiatric Comorbidities and Differential Increases Among Male and Female Participants After Initiating Antiretroviral Therapy in the HIV...
AIDS research and human retroviruses, 2022, Vol.38 (7), p.519-529
7.
Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain
AIDS research and human retroviruses, 2022, Vol.38 (6), p.433-440
8.
A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026)
AIDS research and human retroviruses, 2022, Vol.38 (4), p.257-268
9.
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)
AIDS research and human retroviruses, 2022, Vol.38 (4), p.269-278
10.
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate
AIDS research and human retroviruses, 2022, Vol.38 (4), p.279-287
11.
Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0
by Boers, Maarten
Journal of clinical epidemiology, 2014, Vol.67 (7), p.745-753
12.
Frailty in Comorbid HIV and Lifetime Methamphetamine Use Disorder: Associations with Neurocognitive and Everyday Functioning
by Paolillo, Emily W.
AIDS research and human retroviruses, 2019, Vol.35 (11-12), p.144-1053
13.
Gait Speed Decline Is Associated with Hemoglobin A1C, Neurocognitive Impairment, and Black Race in Persons with HIV
by Masters, Mary Clare
AIDS research and human retroviruses, 2019, Vol.35 (11-12), p.165-1073
14.
Frailty and Its Association with Health Related Quality of Life in Older HIV Patients, in Salvador, Brazil
by Zeballos, Diana
AIDS research and human retroviruses, 2019, Vol.35 (11-12), p.174-1081
15.
Examining Mortality to Identify Opportunities for Improved Care Among Adults with HIV in a Single Academic Medical Center
by Ressler, Adam M.
AIDS research and human retroviruses, 2019, Vol.35 (11-12), p.182-1088
16.
C1q/TNF-Related Proteins, HIV and HIV-Associated Factors, and Cardiometabolic Phenotypes in Middle-Aged Women
by Kasher Meron, Michal
AIDS research and human retroviruses, 2019, Vol.35 (11-12), p.154-1064
17.
Higher Risks of Virologic Failure and All-Cause Deaths Among Older People Living with HIV in Chongqing, China
by Wu, Guohui
AIDS research and human retroviruses, 2019, Vol.35 (11-12), p.195-1102
18.
COVID-19 clinical trials: learning from exceptions in the research chaos
by Tikkinen, Kari A O
Nature medicine, 2020, Vol.26 (11), p.1671-1672
19.
Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis
AIDS research and human retroviruses, 2021, Vol.37 (6), p.421-428
20.
Evaluation of the Safety, Acceptability, and Pharmacokinetic Profile of a Gel Formulation of OB-002 in Healthy Volunteers
AIDS research and human retroviruses, 2021, Vol.37 (6), p.453-460
